Buscar
Mustang Bio Inc
MBIOAñadir a la lista de seguimiento
0.570USD
-0.024-3.97%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
4.32MCap. mercado
PérdidaP/E TTM
Más Datos de Mustang Bio Inc Compañía
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs into potential cures for cancers and autoimmune diseases. The Company has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR T) therapies. Its pipeline is focused in two core areas: CAR T therapies for autoimmune diseases and hematologic malignancies and CAR T therapies for solid tumors. It is developing a CAR T therapy for hematologic malignancies and autoimmune diseases in partnership with Fred Hutchinson Cancer Center targeting CD20 and for solid tumors in partnership with City of Hope National Medical Center targeting IL13Ra2. It has also partnered with Nationwide Children’s Hospital for a herpes simplex virus type 1 oncolytic virus to enhance the activity of MB-101 for the treatment of patients with high-grade malignant brain tumors.
Información de Mustang Bio Inc
Símbolo de cotizaciónMBIO
Nombre de la empresaMustang Bio Inc
Fecha de salida a bolsaAug 22, 2017
Director ejecutivoLitchman (Manuel)
Número de empleados6
Tipo de seguridadOrdinary Share
Fin del año fiscalAug 22
Dirección95 Sawyer Rd
CiudadWALTHAM
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02453
Teléfono17816524500
Sitio Webhttps://www.mustangbio.com/
Símbolo de cotizaciónMBIO
Fecha de salida a bolsaAug 22, 2017
Director ejecutivoLitchman (Manuel)
Ejecutivos de Mustang Bio Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Manuel Litchman, M.D.
Dr. Manuel Litchman, M.D.
President, Chief Executive Officer, Interim Chief Financial Officer, Director
President, Chief Executive Officer, Interim Chief Financial Officer, Director
1.54K
-1.23%
Dr. Michael J. Zelefsky, M.D.
Dr. Michael J. Zelefsky, M.D.
Independent Director
Independent Director
379.00
--
Mr. Adam J. Chill
Mr. Adam J. Chill
Independent Director
Independent Director
375.00
-1.07%
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Director
Director
342.00
--
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Executive Chairman of the Board
Executive Chairman of the Board
325.00
--
Mr. David Jin
Mr. David Jin
Director
Director
286.00
+86.36%
Mr. Neil Herskowitz
Mr. Neil Herskowitz
Independent Director
Independent Director
145.00
-170.34%
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Manuel Litchman, M.D.
Dr. Manuel Litchman, M.D.
President, Chief Executive Officer, Interim Chief Financial Officer, Director
President, Chief Executive Officer, Interim Chief Financial Officer, Director
1.54K
-1.23%
Dr. Michael J. Zelefsky, M.D.
Dr. Michael J. Zelefsky, M.D.
Independent Director
Independent Director
379.00
--
Mr. Adam J. Chill
Mr. Adam J. Chill
Independent Director
Independent Director
375.00
-1.07%
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Director
Director
342.00
--
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Executive Chairman of the Board
Executive Chairman of the Board
325.00
--
Mr. David Jin
Mr. David Jin
Director
Director
286.00
+86.36%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Mustang Bio Inc?
Los cinco principales accionistas de Mustang Bio Inc son: Dr. Manuel Litchman, M.D.
¿Cuántas instituciones poseen acciones de Mustang Bio Inc (MBIO)?
A fecha de 2026Q1, 70 instituciones poseen acciones de Mustang Bio Inc, con un valor de mercado combinado de aproximadamente 664.20K, lo que representa el 9.87% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 196076.00.